Making successful Targeted Alpha Therapy a reality
Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most
potent therapeutic payloads against cancer cells.
Employees in France and the United States
Preclinical laboratories dedicated to the development of alpha therapies
By clicking “I accept Cookies”, you agree with the cookies use to enhance site navigation, analyze site usage and compile statistics. To get more information, please read our Cookies Policy in the Legal Notice